[breadcrumb_custom]

Intellia Therapeutics Inc (NASDAQ: NTLA) Could Make Significant Gains?

In the last trading session, 1.43 million Intellia Therapeutics Inc (NASDAQ:NTLA) shares changed hands as the company’s beta touched 1.75. With the company’s per share price at $29.61 changed hands at $1.38 or 4.89% during last session, the market valuation stood at $2.65B. NTLA’s last price was a discount, traded about -60.35% off its 52-week high of $47.48. The share price had its 52-week low at $22.67, which suggests the last value was 23.44% up since then. When we look at Intellia Therapeutics Inc’s average trading volume, we note the 10-day average is 1.69 million shares, with the 3-month average coming to 0.94.

Intellia Therapeutics Inc (NASDAQ:NTLA) trade information

Instantly NTLA was in green as seen at the end of in last trading. With action 19.20%, the performance over the past five days has been green. The jump to weekly highs of 29.64 added 4.89% to the stock’s daily price. The company’s shares are showing year-to-date downside of -2.89%, with the 5-day performance at 19.20% in the green. However, in the 30-day time frame, Intellia Therapeutics Inc (NASDAQ:NTLA) is 5.19% up. Looking at the short shares, we see there were 10.97 million shares sold at short interest cover period of 7.75 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Intellia Therapeutics Inc (NTLA) estimates and forecasts

Data shows that the Intellia Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -25.06% over the past 6 months, a 12.01% in annual growth rate that is considerably lower than the industry average of 15.50%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Intellia Therapeutics Inc will fall -3.60%, while the growth in revenue is estimated to hit -22.20% for the next quarter. Year-over-year growth is forecast to reach -1.00% down from the last financial year.

Consensus estimates given by 21 financial analysts project the company’s revenue in the current quarter to hit an average of $12.82 million. 13 analysts are of the opinion that Intellia Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $14.92 million. The company’s revenue for the corresponding quarters a year ago was $13.57 million. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -5.50%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -26.79%. The 2024 estimates are for Intellia Therapeutics Inc earnings to increase by 12.40%, but the outlook for the next 5-year period is at 30.00% per year.

NTLA Dividends

Intellia Therapeutics Inc is expected to release its next quarterly earnings report between February 21 and February 26.

On Key

Related Posts